Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
Fengwen Zhang, Jesse Jenkins, Robson Amparo de Carvalho, Sandra Nakandakari-Higa, Teresia Chen, Morgan E. Abernathy, Viren A. Baharani, Elisabeth K. Nyakatura, David Andrew, Irina V. Lebedeva, Ivo C. Lorenz, Hans-Heinrich Hoffmann, Charles M. Rice, Gabriel D. Victora, Christopher O. Barnes, Théodora Hatziioannou, Paul D. Bieniasz
Abstract
Abstract Human monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been isolated from convalescent individuals and developed into therapeutics for SARS-CoV-2 infection. However, therapeutic mAbs for SARS-CoV-2 have been rendered obsolete by the emergence of mAb-resistant virus variants. Here we report the generation of a set of six human mAbs that bind the human angiotensin-converting enzyme-2 (hACE2) receptor, rather than the SARS-CoV-2 spike protein. We show that these antibodies block infection by all hACE2 binding sarbecoviruses tested, including SARS-CoV-2 ancestral, Delta and Omicron variants at concentrations of ~7–100 ng ml −1 . These antibodies target an hACE2 epitope that binds to the SARS-CoV-2 spike, but they do not inhibit hACE2 enzymatic activity nor do they induce cell-surface depletion of hACE2. They have favourable pharmacology, protect hACE2 knock-in mice against SARS-CoV-2 infection and should present a high genetic barrier to the acquisition of resistance. These antibodies should be useful prophylactic and treatment agents against any current or future SARS-CoV-2 variants and might be useful to treat infection with any hACE2-binding sarbecoviruses that emerge in the future.